Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

Open access
Vanpouille-Box, Claire, Diamond, Julie M., Pilones, Karsten A., Zavadil, Jiri, Babb, James S., Formenti, Silvia C., Barcellos-Hoff, Mary Helen, Demaria, Sandra · 2015 · Cancer Research

Published version of a preprint

Abstract

T cells directed to endogenous tumor antigens are powerful mediators of tumor regression. Recent immunotherapy advances have identified effective interventions to unleash tumor-specific T-cell activity in patients who naturally develop them. Eliciting T-cell responses to a patient's individual tumor remains a major challenge. Radiation therapy can induce immune responses to model antigens expressed by tumors, but it remains unclear whether it can effectively prime T cells specific for endogenous antigens expressed by poorly immunogenic tumors. We hypothesized that TGFβ activity is a major obstacle hindering the ability of radiation to generate an in situ tumor vaccine. Here, we show that antibody-mediated TGFβ neutralization during radiation therapy effectively generates CD8(+) T-cell responses to multiple endogenous tumor antigens in poorly immunogenic mouse carcinomas. Generated T cells were effective at causing regression of irradiated tumors and nonirradiated lung metastases or synchronous tumors (abscopal effect). Gene signatures associated with IFNγ and immune-mediated rejection were detected in tumors treated with radiation therapy and TGFβ blockade in combination but not as single agents. Upregulation of programmed death (PD) ligand-1 and -2 in neoplastic and myeloid cells and PD-1 on intratumoral T cells limited tumor rejection, resulting in rapid recurrence. Addition of anti-PD-1 antibodies extended survival achieved with radiation and TGFβ blockade. Thus, TGFβ is a fundamental regulator of radiation therapy's ability to generate an in situ tumor vaccine. The combination of local radiation therapy with TGFβ neutralization offers a novel individualized strategy for vaccinating patients against their tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-3511

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 1

  1. Demaria, 2007, Immunotherapy against metastatic breast cancer with a twist, Breast Cancer Res Treat, 106, S31

Cited by

See all 514

Metadata

Authors
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S.
Affiliations
  • 1Department of Pathology, New York University School of Medicine, New York, New York.
  • New York University (US)
  • 4Department of Radiation Oncology, New York University School of Medicine, New York, New York.
Corresponding author
Demaria, Sandra
Venue
Cancer Research
Published
2015-05-31
Volume
75
Issue
11
Pages
2232-2242
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2045963664
Cited by
514
References
52
Citations by year
2026: 19 · 2025: 34 · 2024: 39 · 2023: 42 · 2022: 48 · 2021: 70 · 2020: 70 · 2019: 45 · 2018: 53 · 2017: 42 · 2016: 42 · 2015: 8
FWCI
21.11
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • U.S. Department of Defense (W81XWH-11-1-, W81XWH1310012, W81XWH, W81XWH1110532, W81XWH-13)
  • Breast Cancer Research Foundation
  • Breast Cancer Alliance
  • Chemotherapy Foundation
  • NYU Langone Medical Center (P30CA016087)
  • Varian Medical Systems
  • National Institutes of Health (W81XWH)
  • National Cancer Institute (P30CA016087)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
TGF-beta, radiotherapy, antitumor immunity, T cell priming, cancer vaccines, TGF-beta neutralization, abscopal effect, PD-1, PD-L1, PD-L2, interferon-gamma, tumor immunogenicity, lung metastasis, tumor recurrence, combination immunotherapy
MeSH terms
Animals, Antigens, Neoplasm, Breast Neoplasms, Combined Modality Therapy, Disease Models, Animal, Female, Humans, Immunotherapy, Neoplasm Recurrence, Local, T-Lymphocytes, Cytotoxic, CD4-Positive T-Lymphocytes, Transforming Growth Factor beta, CD8-Positive T-Lymphocytes, Mice, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-3511
The paper
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015). TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-3511

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.